



Day 0, October 24 th , 2016 13:30 – 15:30	Montserrat A room	Satellite workshop in new technologies
Chair: Dr. Damon Asher 	Merck- Millipore	<p>Dr. Damon Asher is the lead for the Merck Vaccine Initiative in the Americas. His focus is on comprehensive solutions for vaccine manufacturing. Damon previously spent eight years in Merck R&D, where he directed development of new technologies for vaccine purification and biosafety, including methods for production of highly purified TrueSpike™ virus preparations for use in virus spiking studies. Damon holds a Ph.D. in Immunology from Harvard University and a Master's Degree in Biomedical Sciences from Harvard Medical School.</p>
Co-Chair: Mr. Michael Rush 	Temptime Corporation	<p>Michael Rush is currently the Executive Director of Global Health Policy for Temptime Corporation, responsible for developing policies in the goal of improving patient health. Prior to joining Temptime, Mike worked 13 years for Merck Vaccines; he played a major role in vaccine public sector access, funding and policies in the Americas, while collaborating with CDC, HHS and PAHO. He holds a BA in Industrial Psychology and a MBA in International Business Administration.</p>
Dr. Guenter Jagschies 	GE Healthcare	<p>Günter Jagschies is Senior Director with GE, Healthcare Life Sciences with the BioProcess European HQ Division. His current role is Strategic Customer Sweden Relations, working globally with industrial R&D collaborations and as an advisor for the GE Healthcare BioProcess R&D and Business team. He holds a PhD in Biochemistry from the University of Münster, Germany.</p> <p><i>Building efficiencies into processes: Economies of scale and Processes scale up technologies.</i></p>

Dr. Damon Asher



Merck-
Millipore

Dr. Damon Asher is the lead for the Merck Vaccine Initiative in the Americas. His focus is on comprehensive solutions for vaccine manufacturing. Damon previously spent eight years in Merck R&D, where he directed development of new technologies for vaccine purification and biosafety, including methods for production of highly purified TrueSpike™ virus preparations for use in virus spiking studies. Damon holds a Ph.D. in Immunology from Harvard University and a Master's Degree in Biomedical Sciences from Harvard Medical School.

Versatile Technologies for Vaccine Manufacturing.

Dr. Ted Prusik



Temptime
Corporation
USA

Dr. Prusik is the Senior Vice President and one of the Founders of Temptime Corporation, manufacturer of the vaccine vial monitor (VVM). He received his BSc degree in Chemistry from Bucknell University and his MSc and PhD degrees in Chemical Physics from NYU. He joined E.R. Squibb and Sons as research investigator in physical chemistry in 1977 then moved to Allied Corporation in 1981. In 1987, the group was spun off as an independent company.

Temperature control tools and supply chain management.

Mr. Erik Kakes






Applikon

Erik Kakes studied Biochemistry in Rotterdam, the Netherlands. In 1988 he joined Applikon Biotechnology as a project manager. Via the R&D department he moved into Sales to become International Sales & Marketing Director. In 2008 he acquired the ownership of Applikon Biotechnology with Arthur Oudshoorn and Jaap Oostra through a management buyout.

Biosafety as an integral part of facility (re-)design.

Monday 24 th October 18:00 to 18:30	Montserrat room	WELCOME SESSION
Chair: Mr. Mahendra Suhardono 	PT Bio Farma, Indonesia	Marketing director of Bio Farma. Mr. Suhardono joined Bio Farma in 1989 and occupied various positions including Senior Management and Production Directorate. Major successes include the development and licensing of pentavalent (DTP-HB-Hib) vaccine, preparation of pandemic influenza vaccine and being team leader for ISO 9001, ISO 14001 & OHSAS 18001. Nominated President of DCVMN in 2012 after serving on the executive committee since 2010.
Co.Chair: Dr. Alejandro Gil 	Sinergium Biotech	Alejandro Gil serves as President at Sinergium Biotech. With more than 250 employees, Sinergium Biotech is an Argentinian-based Company that provides Human Pharmaceutical world class products. The company investigates, produces and distributes vaccines and biotechnological products. Before Sinergium, since 1984 he acted as Chief Executive Officer of Biogenesis Bagó; a regional biotech company that investigates, develops, produces and sells animal health products and services. President at Caprove (Argentinian Chamber of the industry of Veterinarian Products). He holds a degree in Medical Veterinary.
Dr. Marie Paule Kieny 	WHO	<p>Dr. Kieny is WHO Assistant Director-General for Health Systems and Innovation since November 2012. She was WHO Assistant Director-General for Innovation, Information, Evidence and Research from 2010- 2012. Prior to this, she directed the WHO Initiative for Vaccine Research since its inception in 2001. Before coming to WHO, she held top research positions in the public and private sectors in France. She received her PhD in Microbiology from the University of Montpellier in 1980.</p> <p><i>Global collaborative innovation in vaccines.</i></p>

Day 1, Tuesday October 25 th , 2016 9:00 – 10:00	Montserrat room	Opening session
Chair: Mr. Mahendra Suhardono 	PT Bio Farma, Indonesia	Marketing director of Bio Farma. Mr. Suhardono joined Bio Farma in 1989 and occupied various positions including Senior Management and Production Directorate. Major successes include the development and licensing of pentavalent (DTP-HB-Hib) vaccine, preparation of pandemic influenza vaccine and being team leader for ISO 9001, ISO 14001 & OHSAS 18001. Nominated President of DCMVN in 2012 after serving on the executive committee since 2010.
Co-Chair: Mr. Abel Di Gilio 	Sinergium Biotech	Mr. Di Gilio is the Commercial Director of Sinergium Biotech SA. Before joining Sinergium, he was General Director of Parke Davis Argentina and General Director of Laboratory Elea. He is Ex- President of the Pharmaceutical Marketing Society. Mr. Di Gilio received his Bachelor degree in Business Administration.
Dr. Hugo Sigman 	Group Insud	<p>Founder and CEO of Grupo Insud, a business conglomerate with an active presence in the fields of pharmaceuticals, agroforestry, culture, nature and design.</p> <p>In 1970, he joined the Psychiatry Service of Policlínico Lanús, where he founded the Psychiatric Emergency Unit. Later, he worked in Spain at the Psychiatry Service of Hospital Clínico de Barcelona and where he founded Chemo, a chemical-pharmaceutical company, first company of Grupo Insud. He earned his Medical Doctor degree at the Universidad de Buenos Aires, and also graduated from the Social Psychology School.</p> <p>Welcome speech.</p>

<p>Dr. Jorge Lemus</p> 	<p>Argentinian MOH</p>	<p>Minister of Health of Argentinian Republic earned his Medical Degree in the School of Medicine of the Universidad de Buenos Aires, completing his education as University Specialist in Preventive and Social Medicine and in Clinical Medicine. In the domain of Internal Medicine, he developed his career in the Hospital General de Agudos “Dr. Juan A. Fernández” reaching its direction. He earned a PhD in Medicine by the School of Medicine of the UBA and is an authorized teacher in internal medicine; he has published several articles and earned numerous recognitions.</p> <p><i>Inaugural speech by Argentinian Health Authority.</i></p>
<p>Dr. Carissa F. Etienne</p> 	<p>PAHO</p>	<p>Dr. Etienne is a public health expert and serves as the Director of the PAHO since 2013. She advocates for universal health coverage. She served as the Assistant Director-General of Health Systems and Services at the WHO from 2008-2012, and previously she was the Assistant Director of PAHO. She graduated on Medicine and Surgery from the University of the West Indies, Jamaica, and holds a master’s degree in community health from the London School of Hygiene & Tropical Medicine.</p> <p><i>Video: Comprehensive Immunization: Regional immunization programs in the Americas.</i></p>
<p>Dr. Isabella Danel</p> 	<p>PAHO</p>	<p>Dr. Isabella Danel is the Deputy Director of the Pan American Health Organization (PAHO), Regional Office of WHO for the Americas. Dr. Danel has worked on global health issues at the Centers for Disease Control and Prevention and at the World Bank. She received her MD from Albany Medical College, New York and her MS from the London School of Hygiene and Tropical Medicine. Dr. Danel has written numerous scholarly articles and book chapters on maternal mortality and other public health subjects.</p> <p><i>Continuing partnerships.</i></p>

Tuesday 25 th October 10.30 a.m. to 12.30 p.m.	Montserrat room	Access to Vaccines
Chair: Mr. Rajinder Kumar Suri 	Panacea Biotech	<p>Rajinder has 38 years of experience in Pharmaceuticals & Biological products in India & International markets & over 19 years' experience at the top management including four years on the Board of Directors of Sanofi Pasteur India & Chief Executive-Biologicals, Panacea Biotec and currently engaged as Senior Advisor. Rajinder is Member GAVI-PPC, GAVI Steering Committee Supply & Procurement Strategy, Technical Expert Committee of GAVI's approach in fragile settings and emergencies & has played a lead role in negotiations with Ministry of Health, Government of India, UN agencies like WHO, UNICEF, BMGF & several others.</p>
Co-Chair: Mr. Ray Prasad 	BMGF	<p>Ray Prasad is "Senior CMC Advisor for Vaccine Development" at the Bill & Melinda Gates Foundation. Prior to joining the BMGF, Ray was the Chief Operating Officer and later President for Biological E in India (2008-2016). Under his leadership, Biological E became a global supplier of vaccines, with four new vaccines WHO prequalified in five years, and with a significant enhancement of quality/compliance culture and commercial scale up. Ray was a member of the DCMVN executive committee earlier. Prior to BioE, Ray held senior management positions in US/Europe with major companies.</p>
Ms. Katey Owen 	BMGF	<p>Katey is the Deputy Director for Vaccine Development, Chemistry, Manufacturing, & Controls at the Bill & Melinda Gates Foundation. She joined the foundation in 2013 after spending most of her career in Vaccines at Merck, leading groups in R&D, manufacturing, and commercialization across a broad portfolio of vaccines (Rotavirus, Shingles, MMR, Dengue, HIV, HepA, Hib, HepB, and combination vaccines). She is a virologist by training and scientist at heart, but integrates her manufacturing and profit/strategy experience (including pricing) into vaccine development initiatives.</p> <p><i>Creating stable vaccine supply in developing countries.</i></p>

Dr. Rick Bright



BARDA

Dr. Bright is the Acting Director of the Influenza Division in BARDA, managing advanced projects related to influenza. He also leads the BARDA Influenza Division International Program. He serves as an international expert on influenza. He began his career at the CDC, focused on avian and human influenza viruses. He has also worked in the biotechnology industry and has collaborated with PATH. Dr. Bright received his PhD in Immunology and Molecular Pathogenesis from Emory University and his BS in Biology and Physical Sciences from Auburn University.

Tackling emerging and re-emerging infections.

Dr. Jorge Kalil



Butantan

Jorge Kalil, director of the Butantan Institute is doctor immunologist and professor at the Faculty of Medicine of USP, and is also member of Brazilian Academy of Sciences. He has held several important positions in numerous institutes, committees and associations. Dr. Kalil is the holder of numerous patents, some of new vaccines. He pioneered the deployment of the monoclonal antibody technology in France. He holds a master and Ph.D. in Human Biology by the University of Paris VII.

Vaccines against emerging and re-emerging diseases in tropical regions.


Tuesday 25 th October 14:00 to 15:30	Montserrat room	Vaccine markets, supply and procurement
Chair: Ms. Mahima Datla 	Biological E	<p>Mahima Datla directly oversees strategic operations within Biological E organization and leads the work related to public policy. She has been working with BE for the past 17 years and has served in various capacities across a diverse range of functions. Apart from Biological E, Mahima has served on the steering committee of DCVMN as well as GAVI Board, and she is currently a member of CII National Biotech committees and a GHIT fund board member.</p>
Co-Chair: Mr. Greg Widmyer 	BMGF	<p>Greg Widmyer, deputy director, Vaccine Delivery leads the teams that focus on new vaccine introduction and market innovations; working with GAVI to strengthen country efforts to introduce new vaccines. Prior to joining the foundation, Greg was vice president and general manager of Monogram Biosciences. Prior to joining Monogram, he worked at SCORE Learning. Before, Greg worked for Population Services International in projects on HIV/AIDS. He received his BA in Russian Studies from Yale University and his MBA from Stanford University.</p>
Ms. Melissa Malhame 	GAVI	<p>Melissa Malhame is the Head of Market Shaping at Gavi, who is responsible for working with Alliance partners and industry to ensure adequate supply of appropriate vaccines to meet demand and minimizing the costs of vaccines to Gavi and countries. Prior to Gavi, Melissa has 20 years' experience in multinational companies in leading late stage vaccine development, business, commercial development, marketing and sales, after receiving her MBA degree from the Johnson Graduate School of Management at Cornell University. <i>Gavi vaccine supply and procurement strategy 2016-2020.</i></p>


SPEAKERS BOOK

<p>Ms. Suvi Rautio</p> 	<p>UNICEF</p>	<p>Suvi Rautio is Deputy Director, Supply Programme in UNICEF Supply Division, responsible for vaccines and other health supplies. Previously, she served as Chief of Supply and Procurement in UNICEF India, and prior to that as UNICEF Eastern and Southern Africa Regional Chief of Supply, responsible for supporting 21 countries. She has held several positions in UNICEF Supply Division in Denmark. She has also worked in UNICEF Turkey and Benin country offices. Before joining UNICEF, she worked in the private sector in Taiwan and Hong Kong and with the International Labour Organization in Fiji.</p> <p><i>Innovations in Procurement: Responding to market needs.</i></p>
<p>Mr. John Fitzsimmons</p> 	<p>PAHO</p>	<p>John W. Fitzsimmons is the Chief of the Revolving Fund Special Program for Vaccine Procurement (RFV) at the Pan American Health Organization (PAHO). He has focused the majority of his career in vaccine preventable diseases at WHO's regional offices and at CDC; working to insure the uninterrupted supply of affordable vaccines in support of regional goals for polio eradication, measles and rubella elimination and the introduction of new vaccines. He received a Master's degree in Urban and Regional Planning from the University of Pittsburgh, and has collaborated in various publications.</p> <p><i>Vaccine supply in the Americas: challenges & opportunities.</i></p>
<p>Tuesday 25th October 16:00 to 17:30</p>	<p>Montserrat room</p>	<p>Panel discussion: Building a balanced and sustainable vaccine portfolio</p>
<p>Moderator: Mr. Joshua Chu</p> 	<p>CHAI</p>	<p>Joshua Chu is Senior Director, Global Markets and oversees CHAI's work to increase access to affordable and reliable supply of vaccines. He concurrently holds the role of Senior Regional Program Director, Southeast Asia where he is responsible for the development of new programs in the region. Prior to CHAI, Joshua held several roles including managing investment portfolios of companies in Europe and Asia Pacific.</p> <p>Joshua obtained a Masters in Development from Cambridge University and a BSc from the Wharton School of the University of Pennsylvania.</p> <p><i>Panel discussion: Building a balanced and sustainable vaccine portfolio</i></p>

Day 2, Wed. October 26 th , 2016 9:00 – 10:20	Montserrat A Room	Regulatory Convergence Forum: New approaches to improve access to vaccines in developing countries
Chair: Dr. Jose Luis Di Fabio 	Independent Consultant	<p>Dr. Di Fabio joined PAHO in 1993 as Regional Advisor on Research, Production and Quality Control of Vaccines. In 2003, he became Area Manager of Technology and Health Service Delivery and later on, acting Manager of the Area of Health Systems based on Primary Health Care. From 2011 to 2015, he was the PAHO/WHO Representative in Cuba. Since August 2015 he has been working as an International Consultant. He is author and coauthor of over 100 publications. He has a B.Sc. in Chemistry from Universidad de Uruguay and a Ph.D. in Chemistry from the University of British Columbia.</p>
Co-Chair: Dr. Patricia Aprea 	ANMAT	<p>Dr. Aprea is the Director of Vigilance of Substances Subject to a Special Control in the Department of Biological products of ANMAT. She has a bachelor's degree in Biochemistry</p>
Dr. Carlos Chiale 	ANMAT	<p>PhD in Chemical Sciences. Dr. Chiale is the current director of ANMAT. He has occupied several positions in ANMAT and other institutions like president of the Argentinian Pharmacopoeia, Coordinator of the Commission for Health Products in Mercosur, member of the Anti-counterfeit Drugs Network Officer within others; He has received numerous recognitions such as Honoris Causa Doctorate from UBA, Magnus Price to recognition of the Argentinian Society, Honor Diploma as Emeritus Leader in health, within others. He has published several scientific articles.</p> <p><i>Fostering global collaborations: PIC/S and Mercosur experience.</i></p>


<p>Dr. Daniela Decina</p> 	<p>WHO</p>	<p>Daniela Decina joined the World Health Organization in 2015 as a member of the Regulatory Systems Strengthening Team in the Department of Essential Medicines and Health Products. Since joining WHO her areas of focus have been regulatory strategies for poliovirus vaccine introductions, Good Regulatory Practices guideline development and regulatory pathways for timely registration of medical products. Daniela holds a Master's degree in Microbiology and has more than 25 years of pharmaceutical industry experience in Quality Assurance and Regulatory Affairs.</p> <p><i>Best Regulatory Practices.</i></p>
<p>Dr. Analía Porras</p> 	<p>PAHO</p>	<p>Dr. Porras, national from Argentina, started her career in the Hospital Municipal Teodoro Alvarez, Buenos Aires. In 2004, she served as Senior Fellow at the National Institute for Child Health and Human Development at the National Institutes of Health. In 2007, she joined PAHO, and since 2015, she has been Unit Chief of Medicines and Health Technologies Unit, Department of Health Systems and Services. She holds Medical Degree from the University of Buenos Aires, a PhD in Molecular and Cellular Biology, and a Master in Science in Health Economics, Policy and Management.</p> <p><i>Regional approaches to regulatory convergence.</i></p>
<p>Dr. Nora Dellepiane</p> 	<p>Independent Consultant</p>	<p>With 40 years of experience in production and control of Biological Products, mostly working in vaccine quality and regulation in the last twenty years at WHO, she has experience in quality assurance, quality systems and understanding of GMP. She now focuses her work in assisting manufacturers of Biological Products and regulators to address challenges in the regulation of novel biologicals, including providing training in this field.</p> <p><i>Fostering global dialogue to improve access to vaccines through regulatory convergence.</i></p>



10:45 – 12:00	Montserrat A Room	Panel Discussion ANMAT, PANDRH, WHO, DCVRN, AVAREF, DCVMN
Dr. Nora Dellepiane 	Independent Consultant	<p>With 40 years of experience in production and control of Biological Products, mostly working in vaccine quality and regulation in the last twenty years at WHO, she has experience in quality assurance, quality systems and understanding of GMP. She now focuses her work in assisting manufacturers of Biological Products and regulators to address challenges in the regulation of novel biologicals, including providing training in this field.</p> <p><i>Panel Discussion ANMAT, PANDRH, WHO, DCVRN, AVAREF, DCVMN</i></p>



12:00 12:30	Montserrat A room	Keynote lecture
Dr. Frederik Kristensen 	CEPI	<p>Frederik Kristensen is an experienced healthcare and bio-pharmaceutical executive with experience from the WHO, Merck, Norwegian public health and startups. He is a Medical Doctor with degrees in Public Health (MPH) and Business Administration (MBA). Most recently he worked for the WHO in the Family, Women's and Children's Health cluster as senior advisor to the Assistant Director-General, focused on life-saving commodities, innovation, and public-private partnerships, supporting projects in 20 African and three Asian countries.</p> <p><i>CEPI: A global financing and coordination mechanism to accelerate the development of vaccines against potential epidemics.</i></p>

Wednesday October 26 th , 2016 14:00 – 16:00	Montserrat A Room	Future Vaccines and bioproducts
Chair: Dr. Alexander Precioso 	Instituto Butantan	<p>Alexander R Precioso is Clinical Director of Instituto Butantan, São Paulo with expertise in Clinical Trials, Epidemiology, Pediatrics and vaccine research. He has been responsible for coordinating the integration between the Project Management Office, the Technology Transfer Office, and The Innovation Technology Unit at Butantan institute since 2015. Dr Alexander R. Precioso is member of the Scientific and Technical Council of Butantan Institute, and a member of The Advisory Permanent Committee on Immunization of Secretariat of Health of Sao Paulo State-Brazil.</p>

SPEAKERS BOOK

<p>Co-Chair: Dr. Luis Guillermo Ibarra</p> 	<p>BIRMEX</p>	<p>General Director of Birmex since June 2014. He has a vast experience in several Health Sector institutions in Mexico, having been the Head of the internal Controller of the Ministry of Health, General Director of a Consultant brand for regulations and Mexican norms, and Director of Administration and Quality at the IMSS. Mexican Lawyer with a PhD in Laws at the National Autonomous University of Mexico. He has been professor in several universities in Mexico.</p>
<p>Dr. Maria Elena Bottazzi</p> 	<p>Sabin Vaccine Institute</p>	<p>Deputy Director Sabin Vaccine Institute Product Development Partnership. She is an internationally-recognized scientist with more than 15 years' experience in translational research and vaccine development for neglected tropical diseases. She obtained her degree in Microbiology and Clinical Chemistry in Tegucigalpa, Honduras followed by her Ph.D. in Molecular Immunology and Experimental Pathology at the University of Florida and her post-doctoral training in Cellular Biology at University of Miami and University of Pennsylvania. <i>Advances in Hook worm and Schistosomiasis vaccines.</i></p>
<p>Dr. Valeria Brizzio</p> 	<p>Sinergium Biotech</p>	<p>Dr. Valeria Brizzio is currently Leader of Primary Production and Technical Lead for the Zika vaccine development at Sinergium Biotech. Previously, she served as Project Leader in the Technology Transfer and Business Development departments. Valeria earned her undergraduate degree in Biology from University of Buenos Aires and her PhD in Molecular Biology from Princeton University. <i>Novel flavivirus vaccines.</i></p>
<p>Mr. Siddarth Daga</p> 	<p>VINS</p>	<p>Mr. Siddarth Daga is Executive Director of Vins Bioproducts Limited. He holds a degree in Business Administration from Arizona University, U.S.A. Mr. Daga has a rich experience of more than a decade in the Pharma industry. During his decade long association with Vins Bioproducts Limited, he spear-headed the introduction of several Anti-Sera products which are lifesaving drugs and are exported by the Company to several countries. Mr. Daga is heading the operations of the Company and is responsible for its growth strategies and product diversification. <i>Challenges faced in antisera manufacturing.</i></p>

<p>Dr. Deborah Atherly</p> 	<p>PATH</p>	<p>Deborah Atherly is the Global Head of Policy, Access, and Introduction for PATH's Center for Vaccine Innovation and Access. She develops and advances technologies and interventions to move achievements in immunization research into routine use. She has conducted economic and financial evaluations on drugs and diagnostics for use in developing countries and has held clinical leadership positions in hospitals and health systems. Dr. Atherly is a pharmacist with a PhD in pharmacoconomics and outcomes research.</p> <p><i>Dynamics of vaccines' uptake in Developing Countries' markets.</i></p>
<p>Dr. Yanfeng Lim</p> 	<p>CHAI</p>	<p>As Senior Technical Advisor of the Vaccines Markets Team (VMT) at Clinton Health Access Initiative (CHAI), Yanfeng supports work to sustainably improve access to vaccines for low-income countries. Prior to her current role, Yanfeng was Senior Manager for CHAI's Global vaccines delivery, and strategy manager for TB and HIV within CHAI. Before CHAI, she trained as a biologist at Massachusetts Institute of Technology, and was a consultant at McKinsey & Co. in Chicago.</p> <p><i>Potential future vaccine markets.</i></p>

<p>Wednesday October 26th, 2016 14:00 – 15:40</p>	<p>Quinquela Room</p>	<p>Polio eradication</p>
<p>Chair: Dr. Yao, Yufeng</p> 	<p>IMBCAMS</p>	<p>Dr. Yao, Yufeng, Ph.D and M.D. is the Director of the Department of Quality Control, at the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS). He is also a principal investigator for performing infectious disease and cancer vaccine research, such as HPV and cervical cancer.</p>
<p>Co-Chair: Mr. Michel Zaffran</p> 	<p>Global Polio Eradication Initiative</p>	<p>Michel Zaffran is the Director of Polio Eradication and chair of the strategy Committee of the Global Polio Eradication Initiative. Before that, he headed the WHO Expanded Programme on Immunization. He has also led the WHO/PATH project to Optimize collaboration and was Deputy Executive Secretary at GAVI in charge of policies and technical issues. He holds a master in Engineering from Ecole Centrale de Lyon, France, with subsequent training in Tropical Epidemiology at the Heidelberg University, Germany.</p>

Dr. Jacqueline Fournier



WHO

She joined WHO/HQ in Geneva in 2001 and from this time to now, she has been responsible for the prequalification of polio vaccines and has been serving as regulatory advisor for the Global Polio Eradication Initiative. Before WHO, she used to work for the French National Regulatory Authority in the control and release of viral vaccines.

Regulatory strategies to Polio vaccines and biosafety implementation & monitoring.

Ms. Ann Ottosen



UNICEF

Ann leads the Polio Unit at UNICEF Supply Division and is responsible for the procurement of vaccines including OPV, IPV and Polio Stockpile under the Global Polio Eradication Initiative. Prior to engaging in polio, Ann was responsible for the procurement of New Vaccines including supply planning. Since she joined UNICEF she was involved in the conceptual development of the Advance Market Commitment for pneumococcal vaccines. Ann joined UNICEF in 2007, after 12 years of experience in global vaccine sales and public procurement with a government owned company.

Polio Vaccine Supply for the Switch.

Dr. Birgitte Giersing



WHO

Birgitte Giersing, PhD is a technical officer within the Department of Immunizations, Vaccines and Biologics (IVB) at the WHO. She performed her post-doctoral studies at the NIH, USA in malaria vaccines. She then joined PATH, to oversee development of early stage malaria vaccine candidates. In 2007, Dr Giersing moved into private industry, with both Emergent Biosolutions, and Takeda Vaccines. She joined the WHO in 2014 and is the secretariat for the Product Development Vaccine Advisory Committee (PDVAC), the focal point for several vaccines in development, and the co-chair of WHO's Delivery Technologies Working Group.

Innovation and policy recommendation to ensure vaccine impact.

<p>Mr. Darin Zehrung</p> 	<p>PATH</p>	<p>Darin Zehrung is a global health professional with more than 20 years of technical, business, and research experience with innovations and interventions to address public health challenges in low-resource settings. He is the Portfolio Leader of PATH's Vaccine and Pharmaceutical Delivery Technologies team, overseeing work in the areas of delivery and packaging technologies for vaccines and essential medicines. He currently serves as co-chair of the Delivery Technologies Working Group within the WHO Immunization Practices Advisory Committee (IPAC).</p> <p><i>New technologies to vaccine delivery.</i></p>
<p>Dr. Jayasree K. Iyer</p> 	<p>Access to Medicine Foundation</p>	<p>Jayasree K. Iyer leads the strategic direction, research programmes and stakeholder outreach of the Access to Medicine Foundation. This includes leading the development of the upcoming Access to Vaccines Index, which will report how vaccine companies are improving access to high-priority vaccines for communities in need. Jayasree spearheads the Foundation's discussions with pharmaceutical companies, governments and global health experts, key pharmaceutical industry investors, and with other stakeholders in access to medicine. She holds postgraduate degrees from Singapore University and the John Hopkins School of Hygiene and Public Health.</p> <p><i>Access to vaccines: The powerful role for manufacturers.</i></p>
<p>Wednesday October 26th, 2016 16:20 - 17:00</p>	<p>Montserrat A Room</p>	<p>Partnerships for good</p>
<p>Chair: Dr. Akira Homma</p> 	<p>Bio- Manguinhos/ Fiocruz</p>	<p>Dr. Homma serves as Director of Bio-Manguinhos. Initially, he worked at Bayer, Germany, in the production of vaccines against foot and mouth disease. Later, he coordinated the National Program for Self-Sufficiency in Immunobiology, the Ministry of Health. Responsible for structuring Bio-Manguinhos, articulated agreements with Japanese institutions for the production of several vaccines. In parallel, he has been teaching and researching, with numerous publications. He graduated in Veterinary Medicine from Universidade Federal Fluminense and received his PhD. In Science at Baylor College of Medicine in Houston, United States.</p>

Co-Chair:
Dr. H. Kim



**SK
CHEMICALS**

Dr. Hun Kim is Vice President, Head of VAX Research & Business Development at SK Chemicals Co., Ltd. He started his biopharmaceutical career as a researcher in Green Cross Corporation in 1992. Then he moved to Berna Biotech. He joined SK Chemicals in 2008, under his oversight, the company successfully developed its cell-culture based influenza vaccine products, SKYCellflu and SKYCellflu Qaudrivalent. Dr. Kim graduated from Korea University with a B.S. degree in Agricultural Chemistry, and a M.S. degree in Microbiology. He received his PhD in Biotechnology from Ajou University.

Ms. Shanda Boyle



BMGF

Shanda Boyle is a Program Officer on the Polio team at the Bill & Melinda Gates Foundation where she develops research activities in support of polio eradication, including supporting developing country vaccine manufacturers in the development of Sabin Inactivated polio vaccine (sIPV). In addition, she also supports alternative delivery devices for polio vaccine delivery. Prior to joining the Gates Foundation in 2010, Shanda worked in HIV vaccine development. Shanda completed her MPH and MSc from the University of Washington and also holds a Bachelors of Arts in Political Science.

IPV use and challenges.

Mr. Michel Zaffran



**Global Polio
Eradication
Initiative**

Michel. Zaffran is the Director of Polio Eradication and chair of the strategy Committee of the Global Polio Eradication Initiative. Before that, he headed the WHO Expanded Programme on Immunization. He has also led the WHO/PATH project to Optimize collaboration and was Deputy Executive Secretary at GAVI in charge of policies and technical issues. He holds a master in Engineering from Ecole Centrale de Lyon, France, with subsequent training in Tropical Epidemiology at the Heidelberg University, Germany.

Polio Endgame.